Emilio Ragosa

Securities Offerings

• IPOs for several biotech companies, as well as many underwritten follow-on public offerings
• Several biotech companies with their recent PIPE deals, RDOs, ATM and equity-line offerings
• Several multinational pharma companies in connection with their strategic investments in US public companies
• A medical device company in a reverse merger, now commonly referred to as an alternative public offering
• Several funds in PIPEs and RDOs
• Underwriters in a specialty pharma IPO

Mergers and Acquisitions

• A private biotech company in its sale to a large pharma company for up to US$7 billion
• Combination of a public biotech company client with private biotech and subsequent up-listing on stock exchange
• An Italian specialty pharma company with its acquisition of a US public specialty pharma company
• A public biotech company in its sale to strategic buyer
• A public company in its sale to private equity firm
• A public clinical research organization in several private acquisitions of e-clinical companies
• A public clinical research organization in a public tender offer of a public EDC company
• Multiple private tech and biotech companies in their critical sale transactions

Private Placements

• Private tech and biotech companies with their successful angel and venture financings
• Venture capital firms and other funds with their investments in tech and biotech companies
• Pension funds with investments in private companies

• Selected as Winning Deal Team – Cross-border Turnaround Deal of the Year, Global M&A Network (2021) 
• Life Sciences Star: Finance and Transactional, LMG Life Sciences Guide (2016-2017)
• Chambers USA
  • Band 3, New Jersey Corporate/M&A (2019-2023)
• The Legal 500 United States
  • Recommended, M&A Middle-Market ($500M-999M) (2019)
  • Recommended, Venture Capital & Emerging Companies (2018-2019) 
• 40 Under 40, New Jersey Law Journal (2010)

^{For more information, pursuant to New Jersey Lawyer Advertising guidance, please click here.}